Abstract

Two series of quinoxaline–chalcone conjugates have been prepared by aldolic condensation and aromatic nucleophilic substitution reaction, and their anticancer activity against three cancer cell lines including benign prostatic hyperplasia epithelial cell (BPH-1), neuron-like rat pheochromocytoma cell line (PC12) and human breast cancer cell line (MCF-7) were evaluated in vitro. All of the synthesized compounds exhibited moderate to good activity against the cancer cell lines selected. Particularly, Compound A5 showed the excellent potent activity against BPH-1 and MCF-7 with IC₅₀ values of 10.4 and 9.1 μM, respectively, which is similar to doxorubicin (14.1 and 9.2 μM, respectively). As well as compound B6 exhibited most excellent activity toward PC12 with IC₅₀ values of 16.4 μM. Compound A10 exhibited 55.4, 36.8 and 54.5 folds higher selectivity for BPH-1, PC12 and MCF-7 cells than for HEK-293 cell, respectively. In addition, theoretical biological activities of compounds A5 and A10 were evaluated by SwissADME.

摘要

通过醛糖缩合和芳族亲核取代反应制备了两种喹喔啉-查耳酮缀合物，它们对三种癌细胞系包括良性前列腺增生上皮细胞（BPH-1），神经元样大鼠嗜铬细胞瘤细胞系（ PC12）具有抗癌活性。在体外评估了人乳腺癌细胞系和人乳腺癌细胞系（MCF-7）。所有合成的化合物对所选癌细胞系均表现出中等至良好的活性。特别是，化合物A5对BPH-1和MCF-7表现出优异的有效活性，IC ₅₀值分别为10.4和9.1μM，这与阿霉素相似（分别为14.1和9.2μM）。以及化合物B6对PC12表现出最优异的活性，IC ₅₀值为16.4μM。化合物A10对BPH-1，PC12和MCF-7细胞的选择性分别比对HEK-293细胞高55.4、36.8和54.5倍。此外，SwissADME还评估了化合物A5和A10的理论生物学活性。